Thera-SAbDab

SACITUZUMAB

>   Structural Summary
TherapeuticSacituzumab
TargetTACSTD2
Heavy ChainQVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS
Light ChainDIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG1
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedIBC Pharmaceuticals, Immunomedics, University of Wisconsin Comprehensive Cancer Center, Yale University
Conditions Approvedna
Conditions ActiveBreast cancer, Prostate cancer, Solid tumours, Urogenital cancer, Endometrial cancer
Conditions DiscontinuedPancreatic cancer, Small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]